drugset
drugset / Trial / NCT01845675

Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

NCT01845675 ↗

Phase 2 Completed 14 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelTreatment

Summary

Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor

Timeline

Start
2013-04
Primary completion
2016-11-30
Completion
2017-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 250 mg/m2 Intravenous
Subject Endostar Protein / enzyme biologic 15 mg Intravenous
Subject Temozolomide Small molecule 150 mg/m2 Oral
Subject Temozolomide Small molecule 200 mg/m2 Oral
Subject fluorouracil Small molecule 500 mg/m2 Intravenous

Indications

pancreatic neuroendocrine tumor